Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Stephen A. Harrison*, Federico Perez Manghi, William B. Smith, Diana Alpenidze, Diego Aizenberg, Naomi Klarenbeek, Chi Yi Chen, Eli Zuckerman, Eric Ravussin, Phunchai Charatcharoenwitthaya, Pin Nan Cheng, Helena Katchman, Samuel Klein, Ziv Ben-Ari, Anisha E. Mendonza, Yiming Zhang, Miljen Martic, Shenglin Ma, Sheena Kao, Sandra TannerAlok Pachori, Michael K. Badman, Yan Ling He, Chinweike Ukomadu, Eric Sicard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry